Acquisition · Activity not yet classified
Pharmaceutical Strategies Group's 340B business
Transaction overview
Reported completed
Announced:
Exact closing date not established.
Blue Wolf Capital Partners reported completing the sale of Pharmaceutical Strategies Group's 340B business to Omnicell.
Selected source-supported transactions; coverage is incomplete. Announcements do not establish completion or that a deal is still pending. Sponsor activity and operating-business transactions are distinct from adviser acquisitions. Unclassified activity is excluded from adviser-only counts.
Source evidence
- Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group’s 340B Business to Omnicell ↗
Blue Wolf Capital Partners · Published Oct 2, 2020
Reports completion of Blue Wolf's sale of PSG's 340B business to Omnicell without a separately stated closing day.